Related Experiment Videos
Ligand-binding modes in cationic biogenic amine receptors
1Suntory Institute for Bioorganic Research, 1-1 Wakayamadai, Shimamoto, Osaka 618-8503, Japan. ishiguro@sunbor.or.jp
Chembiochem : a European Journal of Chemical Biology
|September 16, 2004
Summary
Structural models of G protein-coupled receptors reveal how different ligands stabilize distinct receptor conformations. This explains how ligands like agonists and antagonists modulate receptor activity.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- G protein-coupled receptors (GPCRs) possess a binding site within their transmembrane segments.
- Ligand binding induces conformational changes, leading to receptor activation or inactivation.
- GPCRs interact with four classes of ligands: inverse agonists, antagonists, partial agonists, and full agonists.
Purpose of the Study:
- To develop structural models of biogenic amine receptors bound to different functional ligands.
- To investigate ligand-receptor recognition mechanisms based on these models.
- To elucidate how specific ligand interactions stabilize distinct receptor structures.
Main Methods:
- Utilized photointermediate models from the rhodopsin photocascade to build receptor models.
- Modeled receptor-ligand complexes for each of the four functional ligand types.
- Analyzed the structural interactions between ligands and their corresponding receptors.
Main Results:
- Generated putative structural models for biogenic amine receptors in complex with inverse agonists, antagonists, partial agonists, and full agonists.
- Modeling suggested specific binding interactions for each ligand-receptor pair.
- Ligand-specific interactions were identified as key to stabilizing the distinct receptor conformations.
Conclusions:
- The study provides structural insights into GPCR ligand binding and functional modulation.
- Ligand-specific interactions are crucial for stabilizing the conformation of the bound receptor.
- These findings contribute to understanding the molecular basis of GPCR pharmacology.